181 related articles for article (PubMed ID: 34841073)
1. Diagnosis and the importance of early treatment of tyrosinemia type 1: A case report.
Škaričić A; Zekušić M; Fumić K; Rogić D; Uroić V; Petković Ramadža D; Žigman T; Barić I
Clin Mass Spectrom; 2019 Apr; 12():1-6. PubMed ID: 34841073
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genetic characteristics of two patients with tyrosinemia type 1 in Slovenia - A novel fumarylacetoacetate hydrolase (
Sikonja J; Brecelj J; Zerjav Tansek M; Repic Lampret B; Drole Torkar A; Klemencic S; Lipovec N; Stefanova Kralj V; Bertok S; Kovac J; Faganel Kotnik B; Tesarova M; Remec ZI; Debeljak M; Battelino T; Groselj U
Mol Genet Metab Rep; 2022 Mar; 30():100836. PubMed ID: 35242570
[TBL] [Abstract][Full Text] [Related]
3. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D
Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836
[TBL] [Abstract][Full Text] [Related]
4. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D
Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104
[TBL] [Abstract][Full Text] [Related]
5. The genetic tyrosinemias.
Scott CR
Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
[TBL] [Abstract][Full Text] [Related]
6. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
[TBL] [Abstract][Full Text] [Related]
7. Laboratory monitoring of patients with hereditary tyrosinemia type I.
Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
[TBL] [Abstract][Full Text] [Related]
8. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
9. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
10. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
12. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.
Mohamed S; Kambal MA; Al Jurayyan NA; Al-Nemri A; Babiker A; Hasanato R; Al-Jarallah AS
BMC Res Notes; 2013 Sep; 6():362. PubMed ID: 24016420
[TBL] [Abstract][Full Text] [Related]
13. Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.
Varughese B; Madrewar D; Polipalli SK; Kapoor S
Indian J Clin Biochem; 2022 Jan; 37(1):40-50. PubMed ID: 35125692
[TBL] [Abstract][Full Text] [Related]
14. The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening.
Priestley JRC; Alharbi H; Callahan KP; Guzman H; Payan-Walters I; Smith L; Ficicioglu C; Ganetzky RD; Ahrens-Nicklas RC
Int J Neonatal Screen; 2020 Jun; 6(2):. PubMed ID: 32832707
[TBL] [Abstract][Full Text] [Related]
15. Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening.
Hajji H; Imbard A; Spraul A; Taibi L; Barbier V; Habes D; Brassier A; Arnoux JB; Bouchereau J; Pichard S; Sissaoui S; Lacaille F; Girard M; Debray D; de Lonlay P; Schiff M
Mol Genet Metab Rep; 2022 Dec; 33():100933. PubMed ID: 36393896
[TBL] [Abstract][Full Text] [Related]
16. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
17. Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential.
la Marca G; Malvagia S; Pasquini E; Cavicchi C; Morrone A; Ciani F; Funghini S; Villanelli F; Zammarchi E; Guerrini R
JIMD Rep; 2011; 1():107-9. PubMed ID: 23430836
[TBL] [Abstract][Full Text] [Related]
18. Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient
Yang H; Rossignol F; Cyr D; Laframboise R; Wang SP; Soucy JF; Berthier MT; Giguère Y; Waters PJ; Mitchell GA;
Mol Genet Metab Rep; 2018 Mar; 14():55-58. PubMed ID: 29326876
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
